## Csaba Kovesdy

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6321786/publications.pdf

Version: 2024-02-01

492 papers 32,497 citations

92 h-index 159 g-index

500 all docs

500 docs citations

500 times ranked

26642 citing authors

#	Article	IF	CITATIONS
1	Cannabis Use and Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease Transitioning to Dialysis. Cannabis and Cannabinoid Research, 2023, 8, 138-147.	2.9	4
2	High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database. Nephrology Dialysis Transplantation, 2023, 38, 630-643.	0.7	5
3	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrology Dialysis Transplantation, 2023, 38, 372-383.	0.7	13
4	The Impact of RDNs on Non-Communicable Diseases: Proceedings from The State of Food and Nutrition Series Forum. Journal of the Academy of Nutrition and Dietetics, 2022, 122, 166-174.	0.8	2
5	Elevated serum thyrotropin levels and endothelial dysfunction in a prospective hemodialysis cohort. Hemodialysis International, 2022, 26, 57-65.	0.9	3
6	Association of pre-ESKD hyponatremia with post-ESKD outcomes among incident ESKD patients. Nephrology Dialysis Transplantation, 2022, 37, 358-365.	0.7	6
7	Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting. , 2022, 32, e1-e14.		9
8	Global Estimates of Capacity for Kidney Transplantation in World Countries and Regions. Transplantation, 2022, 106, 1113-1122.	1.0	26
9	Association of serum globulin with all-cause mortality in incident hemodialysis patients. Nephrology Dialysis Transplantation, 2022, 37, 1993-2003.	0.7	10
10	Causes and treatment of protein-energy wasting in kidney disease. , 2022, , 191-206.		1
10	Causes and treatment of protein-energy wasting in kidney disease., 2022,, 191-206.  Novel intestinal dialysis interventions and microbiome modulation to control uremia. Current Opinion in Nephrology and Hypertension, 2022, 31, 82-91.	2.0	1 8
	Novel intestinal dialysis interventions and microbiome modulation to control uremia. Current	2.0	
11	Novel intestinal dialysis interventions and microbiome modulation to control uremia. Current Opinion in Nephrology and Hypertension, 2022, 31, 82-91.  Cohort Study and Bias Analysis of the Obesity Paradox Across Stages of Chronic Kidney Disease., 2022,	2.0	8
11 12	Novel intestinal dialysis interventions and microbiome modulation to control uremia. Current Opinion in Nephrology and Hypertension, 2022, 31, 82-91.  Cohort Study and Bias Analysis of the Obesity Paradox Across Stages of Chronic Kidney Disease., 2022, 32, 529-536.  Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD. Clinical Journal of		7
11 12 13	Novel intestinal dialysis interventions and microbiome modulation to control uremia. Current Opinion in Nephrology and Hypertension, 2022, 31, 82-91.  Cohort Study and Bias Analysis of the Obesity Paradox Across Stages of Chronic Kidney Disease., 2022, 32, 529-536.  Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 455-457.  Assessing Global Kidney Nutrition Care. Clinical Journal of the American Society of Nephrology:	4.5	8 7 7
11 12 13	Novel intestinal dialysis interventions and microbiome modulation to control uremia. Current Opinion in Nephrology and Hypertension, 2022, 31, 82-91.  Cohort Study and Bias Analysis of the Obesity Paradox Across Stages of Chronic Kidney Disease., 2022, 32, 529-536.  Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 455-457.  Assessing Global Kidney Nutrition Care. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 38-52.	4.5	8 7 7 23
11 12 13 14	Novel intestinal dialysis interventions and microbiome modulation to control uremia. Current Opinion in Nephrology and Hypertension, 2022, 31, 82-91.  Cohort Study and Bias Analysis of the Obesity Paradox Across Stages of Chronic Kidney Disease., 2022, 32, 529-536.  Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 455-457.  Assessing Global Kidney Nutrition Care. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 38-52.  Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2Ainhibitors. BMC Medicine, 2022, 20, 2.  Warfarin Use, Stroke, and Bleeding Risk among Pre-Existing Atrial Fibrillation US Veterans	4.5 4.5 5.5	8 7 7 23

#	Article	IF	CITATIONS
19	Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements, 2022, 12, 7-11.	14.2	596
20	Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans). American Journal of Cardiology, 2022, 170, 47-55.	1.6	3
21	Associations between APOL1 genetic variants and blood pressure in African American mothers and children from a U.S. pregnancy cohort: Modification by air pollution exposures. Environmental Research, 2022, 212, 113186.	7.5	0
22	OUP accepted manuscript. Nephrology Dialysis Transplantation, 2022, , .	0.7	0
23	Circulating Microbiota in Cardiometabolic Disease. Frontiers in Cellular and Infection Microbiology, 2022, 12, 892232.	3.9	12
24	Serum Thyrotropin Elevation and Coronary Artery Calcification in Hemodialysis Patients. CardioRenal Medicine, 2022, 12, 106-116.	1.9	3
25	Association of Uric Acid–Lowering Therapy With Incident Chronic Kidney Disease. JAMA Network Open, 2022, 5, e2215878.	5.9	19
26	The International Society of Renal Nutrition and Metabolism Commentary on the National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI Clinical Practice Guideline for Nutrition in Chronic Kidney Disease., 2021, 31, 116-120.e1.		49
27	Response to "ls the outcome of SARSâ€CoVâ€2 infection in solid organ transplant recipients really similar to that of the general population?â€. American Journal of Transplantation, 2021, 21, 1672-1673.	4.7	0
28	$\hat{l}^2$ -Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis. American Journal of Kidney Diseases, 2021, 77, 704-712.	1.9	12
29	Nutrition and Obesity Impacts on Kidney Health. Contributions To Nephrology, 2021, 199, 1-19.	1.1	4
30	Potassium Trajectories prior to Dialysis and Mortality following Dialysis Initiation in Patients with Advanced CKD. Nephron, 2021, 145, 265-274.	1.8	4
31	Predialysis Potassium Variability and Postdialysis Mortality in Patients With Advanced CKD. Kidney International Reports, 2021, 6, 366-380.	0.8	8
32	Laxative Use and Risk of Dyskalemia in Patients with Advanced CKD Transitioning to Dialysis. Journal of the American Society of Nephrology: JASN, 2021, 32, 950-959.	6.1	15
33	A call for a better understanding of the role of dietary amino acids and post-translational protein modifications of the microbiome in the progression of CKD. Nephrology Dialysis Transplantation, 2021, 36, 1357-1360.	0.7	4
34	Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease. Seminars in Nephrology, 2021, 41, 96-103.	1.6	8
35	Association between serum osteoprotegerin level and mortality in kidney transplant recipients ―a prospective observational cohort study. Transplant International, 2021, 34, 844-854.	1.6	2
36	Dietary protein intake, kidney function, and survival in a nationally representative cohort. American Journal of Clinical Nutrition, 2021, 114, 303-313.	4.7	12

#	Article	IF	Citations
37	Nomenclature in nephrology: preserving â€renal' and â€nephro' in the glossary of kidney health and disease. Journal of Nephrology, 2021, 34, 639-648.	2.0	11
38	Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database. Mayo Clinic Proceedings, 2021, 96, 975-986.	3.0	19
39	Alignment of diagnosis and pharmacy claims data coding of medication adherence among patients with diabetes or hypertension. Journal of Managed Care & Decialty Pharmacy, 2021, 27, 497-506.	0.9	2
40	Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review. Journal of the American Society of Nephrology: JASN, 2021, 32, 1765-1778.	6.1	13
41	Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes. American Journal of Kidney Diseases, 2021, 77, 739-747.e1.	1.9	29
42	MO516A STRUCTURED EXPERT ELICITATION TO INFORM AND VALIDATE MORTALITY EXTRAPOLATIONS FOR A COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
43	Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes. American Journal of Managed Care, 2021, 27, S168-S177.	1.1	8
44	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	5.2	103
45	Depression screening and clinical outcomes among adults initiating maintenance hemodialysis. CKJ: Clinical Kidney Journal, 2021, 14, 2548-2555.	2.9	4
46	Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. Reviews in Endocrine and Metabolic Disorders, 2021, , $1$ .	5.7	1
47	Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2021, 78, 709-718.	1.9	12
48	Laxative Use and Change in Estimated Glomerular Filtration Rate in Patients With Advanced Chronic Kidney Disease., 2021, 31, 361-369.		9
49	Biologically plausible trends suggesting that a <scp>lowâ€protein</scp> diet may enhance the effect of flozination caused by the sodiumâ€glucose cotransporterâ€⊋ inhibitor dapagliflozin on albuminuria. Diabetes, Obesity and Metabolism, 2021, 23, 2825-2826.	4.4	4
50	Circulating Microbial Signatures and Cardiovascular Death in Patients WithÂESRD. Kidney International Reports, 2021, 6, 2617-2628.	0.8	7
51	Association of dyskalemias with short-term health care utilization in patients with advanced CKD. Journal of Managed Care & Decialty Pharmacy, 2021, 27, 1403-1415.	0.9	3
52	Association of Dyskalemias with Ischemic Stroke in Advanced Chronic Kidney Disease Patients Transitioning to Dialysis. American Journal of Nephrology, 2021, 52, 539-547.	3.1	0
53	Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD. American Journal of Nephrology, 2021, 52, 304-317.	3.1	1
54	Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study. Nephron, 2021, 145, 342-352.	1.8	4

#	Article	IF	CITATIONS
55	Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 75-84.	2.0	25
56	Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study. CKJ: Clinical Kidney Journal, 2021, 14, 1657-1664.	2.9	14
57	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. Nephrology Dialysis Transplantation, 2021, 37, 159-167.	0.7	9
58	Risk of Atherosclerotic Cardiovascular Disease and Nonatherosclerotic Cardiovascular Disease Hospitalizations for Triglycerides Across Chronic Kidney Disease Stages Among 2.9ÂMillion US Veterans. Journal of the American Heart Association, 2021, 10, e022988.	3.7	3
59	Novel Treatments from Inhibition of the Intestinal Sodium–Hydrogen Exchanger 3. International Journal of Nephrology and Renovascular Disease, 2021, Volume 14, 411-420.	1.8	9
60	Should We Let Dialysis Patients Eat Their Fruits and Veggies?. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1781-1783.	4.5	2
61	Alignment of diagnosis and pharmacy claims data coding of medication adherence among patients with diabetes or hypertension. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 497-506.	0.9	0
62	ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease. American Journal of Managed Care, 2021, 27, S360-S368.	1.1	5
63	Association of Mineral Bone Disorder With Decline in Residual Kidney Function in Incident Hemodialysis Patients. Journal of Bone and Mineral Research, 2020, 35, 317-325.	2.8	8
64	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 42-61.	5.2	260
65	Metformin is associated with increase in lactate level in elderly patients with type 2 diabetes and CKD stage 3: A case-control study. Journal of Diabetes and Its Complications, 2020, 34, 107474.	2.3	8
66	Constipation in CKD. Kidney International Reports, 2020, 5, 121-134.	0.8	69
67	Association between postâ€transplant donorâ€specific antibodies and recipient outcomes in simultaneous liver–kidney transplant recipients: singleâ€center, cohort study. Transplant International, 2020, 33, 202-215.	1.6	12
68	Epidemiology of dialysis-treated end-stage renal disease patients in Kazakhstan: data from nationwide large-scale registry 2014–2018. BMC Nephrology, 2020, 21, 407.	1.8	12
69	Laxative use in patients with advanced chronic kidney disease transitioning to dialysis. Nephrology Dialysis Transplantation, 2020, 36, 2018-2026.	0.7	15
70	The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients. Renal Failure, 2020, 42, 1083-1092.	2.1	3
71	Donor hepatitis C antibody positivity misclassifies kidney donor profile index in nonâ€hepatitis Câ€infected donors: time to revise the kidney donor profile index – a retrospective cohort study. Transplant International, 2020, 33, 1732-1744.	1.6	7
72	Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. Annals of Internal Medicine, 2020, 173, 426-435.	3.9	144

#	Article	IF	CITATIONS
73	Mortality Risk in Chronic Kidney Disease Patients Transitioning to Dialysis: Impact of Opiate and Non-Opiate Use. American Journal of Nephrology, 2020, 51, 715-725.	3.1	3
74	Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. American Journal of Transplantation, 2020, 20, 3061-3071.	4.7	89
75	Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database. Journal of Managed Care & Decialty Pharmacy, 2020, 26, 1506-1516.	0.9	12
76	Estimated glomerular filtration rate at dialysis initiation and subsequent decline in residual kidney function among incident hemodialysis patients. Nephrology Dialysis Transplantation, 2020, 35, 1786-1793.	0.7	2
77	Longer Predialysis ACEi/ARB Utilization Is Associated With Reduced Postdialysis Mortality. American Journal of Medicine, 2020, 133, 1065-1073.e3.	1.5	12
78	Association between Posttransplant Opioid Use and Immunosuppressant Therapy Adherence among Renal Transplant Recipients. Nephron, 2020, 144, 321-330.	1.8	4
79	Racial and Regional Disparities in Outcomes Among Veterans Initially Adherent to Oral Antidiabetic Therapies: an Observational Cohort Study. Journal of General Internal Medicine, 2020, 35, 1211-1218.	2.6	1
80	Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. Journal of the American Society of Nephrology: JASN, 2020, 31, 456-468.	6.1	140
81	Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease. Nutrients, 2020, 12, 1931.	4.1	113
82	Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users. BMC Nephrology, 2020, 21, 61.	1.8	5
83	Residual Urine Output and Mortality in a Prospective Hemodialysis Cohort. Kidney International Reports, 2020, 5, 643-653.	0.8	6
84	Real-world management of hyperkalemia with patiromer among United States Veterans. Postgraduate Medicine, 2020, 132, 176-183.	2.0	21
85	Hemodynamic and Laboratory Changes during Incremental Transition from Twice to Thrice-Weekly Hemodialysis. CardioRenal Medicine, 2020, 10, 97-107.	1.9	1
86	Clinical Outcomes of Warfarin Initiation in Advanced Chronic Kidney Disease Patients With Incident Atrial Fibrillation. JACC: Clinical Electrophysiology, 2020, 6, 1658-1668.	3.2	10
87	Lack of Association between Pretransplant Donor-Specific Antibodies and Posttransplant Kidney Outcomes in Simultaneous Liver-Kidney Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Steroid-Free Protocol. Nephron, 2020, 144, 126-137.	1.8	5
88	Association between Nrf2 and CDKN2A expression in patients with end-stage renal disease: a pilot study. Aging, 2020, 12, 16357-16367.	3.1	4
89	Red blood cell distribution width and mortality and hospitalizations in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2019, 34, 2111-2118.	0.7	12
90	Acute kidney injury following coronary revascularization procedures in patients with advanced CKD. Nephrology Dialysis Transplantation, 2019, 34, 1894-1901.	0.7	11

#	Article	IF	CITATIONS
91	Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. Journal of the American Society of Nephrology: JASN, 2019, 30, 1746-1755.	6.1	109
92	A single number for advocacy and communication—worldwide more than 850Âmillion individuals have kidney diseases. Kidney International, 2019, 96, 1048-1050.	5.2	283
93	The gut–kidney–heart axis in chronic kidney disease. Physiology International, 2019, 106, 195-206.	1.6	43
94	Ultrafiltration Rate Effects Declines in Residual Kidney Function in Hemodialysis Patients. American Journal of Nephrology, 2019, 50, 481-488.	3.1	14
95	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ: British Medical Journal, 2019, 367, 15873.	2.3	131
96	Betaâ€blocker practice patterns in chronic kidney disease patients with atrial fibrillation transitioning to hemodialysis. Hemodialysis International, 2019, 23, 506-509.	0.9	1
97	Association of Pre-End-Stage Renal Disease Serum Albumin With Post-End-Stage Renal Disease Outcomes Among Patients Transitioning to Dialysis. , 2019, 29, 310-321.		15
98	Racial and Ethnic Differences in Mortality Associated with Serum Potassium in Incident Peritoneal Dialysis Patients. American Journal of Nephrology, 2019, 50, 361-369.	3.1	9
99	A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Nephrology Dialysis Transplantation, 2019, 34, 1803-1805.	0.7	189
100	History of posttraumatic stress disorder and outcomes after kidney transplantation. American Journal of Transplantation, 2019, 19, 2294-2305.	4.7	6
101	Factors Associated With Withdrawal From Dialysis Therapy in Incident Hemodialysis Patients Aged 80 Years or Older. Journal of the American Medical Directors Association, 2019, 20, 743-750.e1.	2.5	11
102	Vancomycin-Associated Acute Kidney Injury in a Large Veteran Population. American Journal of Nephrology, 2019, 49, 133-142.	3.1	20
103	Machine Learning to Identify Dialysis Patients at High Death Risk. Kidney International Reports, 2019, 4, 1219-1229.	0.8	36
104	Joint associations of obesity and estimated GFR with clinical outcomes: a population-based cohort study. BMC Nephrology, 2019, 20, 204.	1.8	3
105	Clinical trials in end-stage renal diseaseâ€"priorities and challenges. Nephrology Dialysis Transplantation, 2019, 34, 1084-1089.	0.7	11
106	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1027-1036.	5.2	60
107	The TiME Trial: A Fully Embedded, Cluster-Randomized, Pragmatic Trial of Hemodialysis Session Duration. Journal of the American Society of Nephrology: JASN, 2019, 30, 890-903.	6.1	38
108	Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States. American Journal of Kidney Diseases, 2019, 74, 23-35.	1.9	13

#	Article	IF	CITATIONS
109	Statin Therapy Before Transition to Endâ€Stage Renal Disease With Posttransition Outcomes. Journal of the American Heart Association, 2019, 8, e011869.	3.7	13
110	Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease. Cannabis and Cannabinoid Research, 2019, 4, 10-20.	2.9	29
111	Relation of Obesity to Outcomes of Hospitalizations for Atrial Fibrillation. American Journal of Cardiology, 2019, 123, 1448-1452.	1.6	11
112	Association Between Serum Prealbumin Level and Outcomes in Prevalent Kidney Transplant Recipients. , 2019, 29, 188-195.		7
113	Serum Metabolites and Cardiac Death in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 747-749.	4.5	11
114	US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2019, 73, A7-A8.	1.9	680
115	Real-World Evaluation of Patiromer forÂtheÂTreatment of Hyperkalemia inÂHemodialysis Patients. Kidney International Reports, 2019, 4, 301-309.	0.8	38
116	Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. Journal of Clinical Lipidology, 2019, 13, 744-753.e15.	1.5	19
117	Fluctuations in plasma potassium in patients on dialysis. Nephrology Dialysis Transplantation, 2019, 34, iii19-iii25.	0.7	5
118	Constipation and risk of death and cardiovascular events. Atherosclerosis, 2019, 281, 114-120.	0.8	128
119	Predialysis coronary revascularization and postdialysis mortality. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 976-983.e7.	0.8	7
120	Glycemic Status and Mortality in Chronic Kidney Disease According to Transition Versus Nontransition to Dialysis., 2019, 29, 82-90.		7
121	Association between malnutrition–inflammation score and risk of subsequent self-reported bone fractures in prevalent kidney transplant recipients. Osteoporosis International, 2019, 30, 611-620.	3.1	4
122	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	11.4	199
123	Early Mortality Among Peritoneal Dialysis and Hemodialysis Patients Who Transitioned With an Optimal OutpatientÂStart. Kidney International Reports, 2019, 4, 275-284.	0.8	14
124	Mean Corpuscular Volume and Mortality in Incident Hemodialysis Patients. Nephron, 2019, 141, 188-200.	1.8	11
125	Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. American Journal of Kidney Diseases, 2019, 73, 206-217.	1.9	49
126	Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality. Nephrology Dialysis Transplantation, 2019, 34, 2095-2104.	0.7	20

#	Article	IF	Citations
127	Glucose Homeostasis and the Burnt-Out Diabetes Phenomenon in Patients with Kidney Disease. , 2019, , 27-38.		0
128	Radical versus partial nephrectomy, chronic kidney disease progression and mortality in US veterans. Nephrology Dialysis Transplantation, 2018, 33, gfw358.	0.7	23
129	Prognostic significance of pre-end-stage renal disease serum alkaline phosphatase for post-end-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis. Nephrology Dialysis Transplantation, 2018, 33, gfw412.	0.7	22
130	US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2018, 71, A7.	1.9	554
131	Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney International, 2018, 93, 1207-1216.	5.2	37
132	Impact of residual kidney function on hemodialysis adequacy and patient survival. Nephrology Dialysis Transplantation, 2018, 33, 1823-1831.	0.7	9
133	Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. Journal of Clinical Lipidology, 2018, 12, 488-497.	1.5	15
134	In response to †benefits and risks of intensive bloodâ€pressure lowering in advanced chronic kidney disease'. Journal of Internal Medicine, 2018, 283, 607-610.	6.0	1
135	Association of Pre-ESRD Serum Calcium With Post-ESRD Mortality Among Incident ESRD Patients: A Cohort Study. Journal of Bone and Mineral Research, 2018, 33, 1027-1036.	2.8	17
136	History of psychosis and mania, and outcomes after kidney transplantation - a retrospective study. Transplant International, 2018, 31, 554-565.	1.6	14
137	Association of Ultrafiltration Rate with Mortality in Incident Hemodialysis Patients. Nephron, 2018, 139, 13-22.	1.8	27
138	The Authors' Reply. Transplantation, 2018, 102, e87.	1.0	0
139	Abrupt Decline in Kidney Function Precipitating Initiation of Chronic Renal Replacement Therapy. Kidney International Reports, 2018, 3, 602-609.	0.8	13
140	Impact of Obesity on Modality Longevity, Residual Kidney Function, Peritonitis, and Survival Among Incident Peritoneal Dialysis Patients. American Journal of Kidney Diseases, 2018, 71, 802-813.	1.9	46
141	Disparities in early mortality among chronic kidney disease patients who transition to peritoneal dialysis and hemodialysis with and without catheters. International Urology and Nephrology, 2018, 50, 963-971.	1.4	22
142	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. European Heart Journal, 2018, 39, 1535-1542.	2.2	218
143	Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrology Dialysis Transplantation, 2018, 33, 149-159.	0.7	110
144	Association of the frequency of pre-end-stage renal disease medical care with post-end-stage renal disease mortality and hospitalization. Nephrology Dialysis Transplantation, 2018, 33, 789-795.	0.7	6

#	Article	IF	CITATIONS
145	Estimated glomerular filtration rate and the risk–benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial. Journal of Internal Medicine, 2018, 283, 314-327.	6.0	52
146	Lowâ€protein diet for conservative management of chronic kidney disease: a systematic review and metaâ€analysis of controlled trials. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 235-245.	7.3	141
147	Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients. Nephrology Dialysis Transplantation, 2018, 33, 1207-1214.	0.7	39
148	No Survival Benefit in Octogenarians and Nonagenarians with Extended Hemodialysis Treatment Time. American Journal of Nephrology, 2018, 48, 389-398.	3.1	4
149	Introduction to treatment considerations in conventional hemodialysis ―What we know. Seminars in Dialysis, 2018, 31, 535-536.	1.3	0
150	Association of Chronic Insomnia With Mortality and Adverse Renal Outcomes. Mayo Clinic Proceedings, 2018, 93, 1563-1570.	3.0	21
151	Impact of pharmacy services on initial clinical outcomes and medication adherence among veterans with uncontrolled diabetes. BMC Health Services Research, 2018, 18, 855.	2.2	15
152	Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA Network Open, 2018, 1, e182311.	5.9	31
153	Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease. Diagnostics, 2018, 8, 71.	2.6	15
154	CKD in African Americans as a Complex Intertwining of Biology and Socioeconomics: An Introduction. American Journal of Kidney Diseases, 2018, 72, S1-S2.	1.9	2
155	Global Prevalence of Protein-Energy Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational Studies From the International Society of Renal Nutrition and Metabolism., 2018, 28, 380-392.		225
156	Fetalâ€"Not Maternalâ€"APOL1 Genotype Associated with Risk for Preeclampsia in Those with African Ancestry. American Journal of Human Genetics, 2018, 103, 367-376.	6.2	49
157	Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes. American Journal of Nephrology, 2018, 47, 333-342.	3.1	12
158	Protein Energy Wasting in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1558-1560.	4.5	10
159	Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction. American Heart Journal, 2018, 205, 53-62.	2.7	10
160	Precision Medicine for Nutritional Management in End-Stage Kidney Disease and Transition to Dialysis. Seminars in Nephrology, 2018, 38, 383-396.	1.6	30
161	Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis. American Journal of Kidney Diseases, 2018, 72, 701-710.	1.9	17
162	Dialysis Provider and Outcomes among United States Veterans Who Transition to Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1055-1062.	4.5	15

#	Article	IF	Citations
163	Patient-Centered Approach for Hypertension Management in End-Stage Kidney Disease: Art or Science?. Seminars in Nephrology, 2018, 38, 355-368.	1.6	O
164	Disparities in Initial Oral Antidiabetic Medication Adherence Among Veterans with Incident Diabetes. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 379-389.	0.9	12
165	Differences in health outcomes associated with initial adherence to oral antidiabetes medications among veterans with uncomplicated Type 2 diabetes: a 5â€year survival analysis. Diabetic Medicine, 2018, 35, 1571-1579.	2.3	10
166	Predialysis Kidney Function and Its Rate of Decline Predict Mortality and Hospitalizations After Starting Dialysis. Mayo Clinic Proceedings, 2018, 93, 1074-1085.	3.0	11
167	Dietary Approach to Recurrent or Chronic Hyperkalaemia in Patients with Decreased Kidney Function. Nutrients, 2018, 10, 261.	4.1	121
168	Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: AÂRandomized Controlled Trial. Kidney International Reports, 2018, 3, 897-904.	0.8	10
169	Thyroid Status and Death Risk in US Veterans With Chronic Kidney Disease. Mayo Clinic Proceedings, 2018, 93, 573-585.	3.0	22
170	Development and Validation of Prediction Scores for Early Mortality at Transition to Dialysis. Mayo Clinic Proceedings, 2018, 93, 1224-1235.	3.0	16
171	Inverse Association Between Serum Non–Highâ€Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. Journal of the American Heart Association, 2018, 7, .	3.7	20
172	Evidence of chronic kidney disease in veterans with incident diabetes mellitus. PLoS ONE, 2018, 13, e0192712.	2.5	26
173	Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial. Nephrology Dialysis Transplantation, 2017, 32, gfw323.	0.7	24
174	Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort. Nephrology Dialysis Transplantation, 2017, 32, 370-377.	0.7	11
175	Association of serum vitamin B12 and folate with mortality in incident hemodialysis patients. Nephrology Dialysis Transplantation, 2017, 32, 1024-1032.	0.7	36
176	Serum uric acid, protein intake and mortality in hemodialysis patients. Nephrology Dialysis Transplantation, 2017, 32, gfw419.	0.7	49
177	Obesity and kidney disease: Hidden consequences of the epidemic. Journal of Renal Care, 2017, 43, 3-10.	1.2	12
178	Obesity and kidney disease: Hidden consequences of the epidemic. Nephrology, 2017, 22, 191-198.	1.6	0
179	Obesity and kidney disease: hidden consequences of the epidemic. Journal of Nephrology, 2017, 30, 1-10.	2.0	42
180	Blood Pressure Before Initiation of Maintenance Dialysis and Subsequent Mortality. American Journal of Kidney Diseases, 2017, 70, 207-217.	1.9	28

#	Article	lF	Citations
181	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. , 2017, 27, 75-77.		25
182	US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2017, 69, A7-A8.	1.9	716
183	Obesity and kidney disease: Hidden consequences of the epidemic. Nephrologie Et Therapeutique, 2017, 13, 131-137.	0.5	0
184	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Blood Purification, 2017, 43, 346-354.	1.8	12
185	Reply. Journal of the American College of Cardiology, 2017, 69, 908-909.	2.8	0
186	Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 591-602.	4.5	42
187	Obesity and kidney disease: hidden consequences of the epidemic. Pediatric Nephrology, 2017, 32, 537-545.	1.7	5
188	Obesity and kidney disease: hidden consequences of the epidemic. Internal Medicine Journal, 2017, 47, 134-143.	0.8	4
189	Disease Trajectories Before ESRD: Implications for Clinical Management. Seminars in Nephrology, 2017, 37, 132-143.	1.6	26
190	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Nephron, 2017, 135, 243-251.	1.8	10
191	Obesidad y enfermedad renal: consecuencias ocultas de la epidemia. Nefrologia, 2017, 37, 360-369.	0.4	12
192	Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease. Seminars in Dialysis, 2017, 30, 251-261.	1.3	31
193	Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1118-1127.	4.5	26
194	Longitudinal Associations among Renal Urea Clearance–Corrected Normalized Protein Catabolic Rate, Serum Albumin, and Mortality in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1109-1117.	4.5	49
195	Pre-ESRD Dementia and Post-ESRD Mortality in a Large Cohort of Incident Dialysis Patients. Dementia and Geriatric Cognitive Disorders, 2017, 43, 281-293.	1.5	5
196	Obesity and Kidney Disease. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769866.	1.1	116
197	Early Mortality Associated with Inpatient versus Outpatient Hemodialysis Initiation in a Large Cohort of US Veterans with Incident End-Stage Renal Disease. Nephron, 2017, 137, 15-22.	1.8	22
198	Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes. American Journal of Nephrology, 2017, 45, 431-441.	3.1	6

#	Article	IF	Citations
199	Obesity and kidney disease: hidden consequences of the epidemic. Future Science OA, 2017, 3, FSO159.	1.9	9
200	Obesity and kidney disease: Hidden consequences of the epidemic. Physiology International, 2017, 104, 1-14.	1.6	46
201	Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrology Dialysis Transplantation, 2017, 32, 157-164.	0.7	55
202	Obesity and kidney disease: hidden consequences of the epidemic. Nephrology Dialysis Transplantation, 2017, 32, 203-210.	0.7	8
203	Association of Restless Legs Syndrome With Incident Parkinson's Disease. Sleep, 2017, 40, .	1.1	33
204	Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes. Diabetes Care, 2017, 40, 1050-1057.	8.6	26
205	Effect of Age on the Association of Vascular Access Type with Mortality in a Cohort of Incident End-Stage Renal Disease Patients. Nephron, 2017, 137, 57-63.	1.8	18
206	Obesity and kidney disease: hidden consequences of the epidemic. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2017, 22, 5-11.	0.2	12
207	Thyroid Status and Mortality in a Prospective Hemodialysis Cohort. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1568-1577.	3.6	30
208	DASH-ing toward improved renal outcomes: when healthy nutrition prevents incident chronic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, ii231-ii233.	0.7	3
209	Hypertension in chronic kidney disease after the Systolic Blood Pressure Intervention Trial: targets, treatment and current uncertainties. Nephrology Dialysis Transplantation, 2017, 32, ii219-ii223.	0.7	9
210	Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2017, 32, ii91-ii98.	0.7	71
211	Seasonal variations in transition, mortality and kidney transplantation among patients with end-stage renal disease in the USA. Nephrology Dialysis Transplantation, 2017, 32, ii99-ii105.	0.7	16
212	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. American Journal of Nephrology, 2017, 45, 283-291.	3.1	1,557
213	Changes in urine volume and serum albumin in incident hemodialysis patients. Hemodialysis International, 2017, 21, 507-518.	0.9	8
214	Obesity and kidney disease: hidden consequences of the epidemic. Kidney International, 2017, 91, 260-262.	<b>5.2</b>	47
215	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. Journal of the American Society of Hypertension, 2017, 11, 783-800.	2.3	81
216	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. American Journal of Kidney Diseases, 2017, 70, 844-858.	1.9	53

#	Article	IF	Citations
217	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. American Journal of Hypertension, 2017, 30, 328-336.	2.0	11
218	Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1941-1949.	4.5	38
219	The Ideal Blood Pressure Target for Patients With Chronic Kidney Diseaseâ€"Searching for the Sweet Spot. JAMA Internal Medicine, 2017, 177, 1506.	5.1	4
220	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes and Endocrinology,the, 2017, 5, 718-728.	11.4	110
221	Lung Function and Incident Kidney Disease: The Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2017, 70, 675-685.	1.9	32
222	Cannabinoids and the kidney: effects in health and disease. American Journal of Physiology - Renal Physiology, 2017, 313, F1124-F1132.	2.7	33
223	Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney Function. Circulation: Heart Failure, 2017, 10, .	3.9	35
224	Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Kidney Diseases (Basel, Switzerland), 2017, 3, 33-41.	2.5	12
225	New options for the management of chronic hyperkalemia. Kidney International Supplements, 2017, 7, 164-170.	14.2	19
226	Changing the paradigms for the treatment of chronic kidney disease. Kidney International Supplements, 2017, 7, 155-156.	14.2	1
227	Lymphocyte Cell Ratios and Mortality among Incident Hemodialysis Patients. American Journal of Nephrology, 2017, 46, 408-416.	3.1	53
228	Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis. American Journal of Nephrology, 2017, 46, 397-407.	3.1	16
229	Pre-end-stage renal disease visit-to-visit systolic blood pressure variability and post-end-stage renal disease mortality in incident dialysis patients. Journal of Hypertension, 2017, 35, 1816-1824.	0.5	13
230	Inflammatory Markers and Outcomes in Kidney Transplant Recipients. Transplantation, 2017, 101, 2152-2164.	1.0	16
231	Pre-ESRD Depression and Post-ESRD Mortality in Patients with Advanced CKD Transitioning to Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1428-1437.	4.5	28
232	Constipation and Incident CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 1248-1258.	6.1	89
233	Concurrence of Serum Creatinine and Albumin With Lower Risk for Death in Twice-Weekly Hemodialysis Patients., 2017, 27, 26-36.		18
234	Updates in hyperkalemia: Outcomes and therapeutic strategies. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 41-47.	5.7	73

#	Article	IF	Citations
235	Association Between Serum Leptin Level and Mortality in Kidney Transplant Recipients., 2017, 27, 53-61.		10
236	Development and Validation of a Novel Laboratory-Specific Correction Equation for Total Serum Calcium and Its Association With Mortality Among Hemodialysis Patients. Journal of Bone and Mineral Research, 2017, 32, 549-559.	2.8	11
237	Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4648-4657.	3.6	11
238	Obesity and kidney disease: hidden consequences of the epidemic. CKJ: Clinical Kidney Journal, 2017, 10, 1-8.	2.9	40
239	Obesity and kidney disease: Hidden consequences of the epidemic. African Journal of Primary Health Care and Family Medicine, 2017, 9, e1-e3.	0.8	14
240	Obesity and kidney disease: hidden consequences of the epidemic. Brazilian Journal of Medical and Biological Research, 2017, 50, e6075.	1.5	12
241	Obesity and kidney disease: hidden consequences of the epidemic. Revista Medica De Chile, 2017, 145, 281-291.	0.2	8
242	OBESITY AND KIDNEY DISEASE: HIDDEN CONSEQUENCES OF THE EPIDEMIC. Nephrology (Saint-Petersburg), 2017, 21, 10-19.	0.4	2
243	Obesity and kidney disease: Hidden consequences of the epidemic. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017, 28, 241.	0.3	5
244	Obesity and kidney disease: Hidden consequences of the epidemic. Indian Journal of Nephrology, 2017, 27, 85.	0.5	43
245	Age, Race and Cardiovascular Outcomes in African American Veterans. Ethnicity and Disease, 2016, 26, 305.	2.3	8
246	Synergistic association of combined glycemic and blood pressure level with risk of complications in US veterans with diabetes. Journal of Hypertension, 2016, 34, 907-913.	0.5	18
247	Serum sodium and mortality in a national peritoneal dialysis cohort. Nephrology Dialysis Transplantation, 2016, 32, gfw254.	0.7	20
248	Changes in serum cystatin C, creatinine, and Câ€reactive protein after cardiopulmonary bypass in patients with normal preoperative kidney function. Nephrology, 2016, 21, 519-525.	1.6	12
249	Association between serum resistin level and outcomes in kidney transplant recipients. Transplant International, 2016, 29, 352-361.	1.6	7
250	North American experience with Low protein diet for Non-dialysis-dependent chronic kidney disease. BMC Nephrology, 2016, 17, 90.	1.8	57
251	Association of Abdominal Circumference, Body Mass Index, and Inflammation in Kidney Transplant Recipients., 2016, 26, 325-333.		11
252	Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2440-2449.	3.6	26

#	Article	IF	CITATIONS
253	Predialysis Cardiovascular Disease Medication Adherence and Mortality After Transition to Dialysis. American Journal of Kidney Diseases, 2016, 68, 609-618.	1.9	53
254	Age and Outcomes Associated with BP in Patients with Incident CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 821-831.	4.5	67
255	Association of aspartate aminotransferase with mortality in hemodialysis patients. Nephrology Dialysis Transplantation, 2016, 31, 814-822.	0.7	16
256	Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2016, 27, 3758-3768.	6.1	126
257	Pain and Kidney Function Decline and Mortality: A CohortÂStudyÂof US Veterans. American Journal of Kidney Diseases, 2016, 68, 240-246.	1.9	20
258	Survival of Elderly Adults Undergoing Incident Home Hemodialysis and Kidney Transplantation. Journal of the American Geriatrics Society, 2016, 64, 2003-2010.	2.6	18
259	The Reply. American Journal of Medicine, 2016, 129, e93.	1.5	0
260	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Pharmacological Research, 2016, 113, 585-591.	7.1	91
261	Mean platelet volume and mortality risk in a national incident hemodialysis cohort. International Journal of Cardiology, 2016, 220, 862-870.	1.7	16
262	Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrology Dialysis Transplantation, 2016, 31, 1310-1319.	0.7	51
263	Association of incident restless legs syndrome with outcomes in a large cohort of <scp>US</scp> veterans. Journal of Sleep Research, 2016, 25, 47-56.	3.2	48
264	Malnutrition in Dialysis Patientsâ€"The Need for Intervention Despite Uncertain Benefits. Seminars in Dialysis, 2016, 29, 28-34.	1.3	14
265	Thyroid Functional Disease and Mortality in a National Peritoneal Dialysis Cohort. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4054-4061.	3.6	36
266	Treatment frequency and mortality among incident hemodialysis patients in the United States comparing incremental with standard and more frequent dialysis. Kidney International, 2016, 90, 1071-1079.	5.2	53
267	Racial Differences in Association of Serum Calcium with Mortality and Incident Cardio- and Cerebrovascular Events. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4851-4859.	3.6	13
268	Association of Systolic Blood Pressure Variability With Mortality, CoronaryÂHeartÂDisease, Stroke, andÂRenalÂDisease. Journal of the American College of Cardiology, 2016, 68, 1375-1386.	2.8	211
269	Comparisons of sleep apnoea rate and outcomes among patients with resistant and nonâ€resistant hypertension. Respirology, 2016, 21, 1486-1492.	2.3	12
270	Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies. Current Cardiology Reports, 2016, 18, 88.	2.9	7

#	Article	IF	Citations
271	Association of body weight changes with mortality in incident hemodialysis patients. Nephrology Dialysis Transplantation, 2016, 32, gfw373.	0.7	21
272	SP655ASSOCIATION OF ABDOMINAL CIRCUMFERENCE AND INFLAMMATION IN KIDNEY TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2016, 31, i313-i313.	0.7	0
273	Response to Letter Regarding Article, "Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans― Circulation, 2016, 133, e453.	1.6	1
274	FGF23 from bench to bedside. American Journal of Physiology - Renal Physiology, 2016, 310, F1168-F1174.	2.7	56
275	Increased Risk of Incident Chronic Kidney Disease, Cardiovascular Disease, and Mortality in Patients With Diabetes With Comorbid Depression. Diabetes Care, 2016, 39, 1940-1947.	8.6	71
276	Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? No, We Should Never Again Compromise Safety!. Diabetes Care, 2016, 39, 1281-1286.	8.6	30
277	Association between vascular access creation and deceleration of estimated glomerular filtration rate decline in late-stage chronic kidney disease patients transitioning to end-stage renal disease. Nephrology Dialysis Transplantation, 2016, 32, gfw220.	0.7	62
278	Pragmatic Clinical Trials in CKD: Opportunities and Challenges. Journal of the American Society of Nephrology: JASN, 2016, 27, 2948-2954.	6.1	39
279	Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure. JAMA - Journal of the American Medical Association, 2016, 315, 164.	7.4	450
280	Past Decline Versus Current eGFR and Subsequent ESRD Risk. Journal of the American Society of Nephrology: JASN, 2016, 27, 2447-2455.	6.1	78
281	Epidemiology of hyperkalemia: an update. Kidney International Supplements, 2016, 6, 3-6.	14.2	33
282	Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis. CardioRenal Medicine, 2016, 6, 37-49.	1.9	83
283	US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2016, 67, A7-A8.	1.9	440
284	Candidate Surrogate End Points for ESRD after AKI. Journal of the American Society of Nephrology: JASN, 2016, 27, 2851-2859.	6.1	47
285	Back to the future: restricted protein intake for conservative management of CKD, triple goals of renoprotection, uremia mitigation, and nutritional health. International Urology and Nephrology, 2016, 48, 725-729.	1.4	35
286	Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study. American Journal of Kidney Diseases, 2016, 68, 256-265.	1.9	186
287	Association of Slopes of Estimated Glomerular Filtration Rate With Post–End-Stage Renal Disease Mortality in Patients With Advanced Chronic Kidney Disease Transitioning to Dialysis. Mayo Clinic Proceedings, 2016, 91, 196-207.	3.0	47
288	Red Cell Distribution Width and Mortality inÂHemodialysisÂPatients. American Journal of Kidney Diseases, 2016, 68, 110-121.	1.9	70

#	Article	IF	Citations
289	Pre-dialysis serum sodium and mortality in a national incident hemodialysis cohort. Nephrology Dialysis Transplantation, 2016, 31, 992-1001.	0.7	41
290	Lean Body Mass and Survival in Hemodialysis Patients and the Roles of Race and Ethnicity. , 2016, 26, 26-37.		39
291	Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. New England Journal of Medicine, 2016, 374, 411-421.	27.0	354
292	Association of Body Mass Index with Mortality in Peritoneal Dialysis Patients: A Systematic Review and Meta-Analysis. Peritoneal Dialysis International, 2016, 36, 315-325.	2.3	43
293	Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data. American Journal of Kidney Diseases, 2016, 67, 872-880.	1.9	216
294	Evaluation and management of diabetic and non-diabetic hypoglycemia in end-stage renal disease. Nephrology Dialysis Transplantation, 2016, 31, 8-15.	0.7	32
295	Association of Pre-Operative Albuminuria with Post-Operative Outcomes after Coronary Artery Bypass Grafting. Scientific Reports, 2015, 5, 16458.	3.3	9
296	Latest consensus and update on protein-energy wasting in chronic kidney disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 254-262.	2.5	210
297	Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans. American Journal of Nephrology, 2015, 42, 151-157.	3.1	16
298	Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology, 2015, 61, 1495-1502.	7.3	149
299	Comparison of the malnutrition–inflammation score in chronic kidney disease patients and kidney transplant recipients. International Urology and Nephrology, 2015, 47, 1025-1033.	1.4	16
300	Association of Thyroid Functional Disease With Mortality in a National Cohort of Incident Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1386-1395.	3.6	57
301	Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1238-1247.	6.1	<b>7</b> 5
302	Dietary Restrictions in Dialysis Patients: Is There Anything Left to Eat?. Seminars in Dialysis, 2015, 28, 159-168.	1.3	157
303	Niacin and Progression of CKD. American Journal of Kidney Diseases, 2015, 65, 785-798.	1.9	24
304	Hypomagnesemia and Mortality in Incident HemodialysisÂPatients. American Journal of Kidney Diseases, 2015, 66, 1047-1055.	1.9	63
305	US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases, 2015, 66, A7.	1.9	484
306	Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes and Endocrinology, the, 2015, 3, 704-714.	11.4	156

#	Article	IF	CITATIONS
307	Changes in Pulse Pressure during Hemodialysis Treatment and Survival in Maintenance Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1179-1191.	4.5	22
308	Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans. Thorax, 2015, 70, 888-895.	5 <b>.</b> 6	120
309	Management of Hyperkalemia: An Update for the Internist. American Journal of Medicine, 2015, 128, 1281-1287.	1.5	94
310	Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. American Journal of Kidney Diseases, 2015, 66, 313-321.	1.9	49
311	Bicarbonate Therapy in Endâ€Stage Renal Disease: Current Practice Trends and Implications. Seminars in Dialysis, 2015, 28, 370-376.	1.3	10
312	Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans. Circulation, 2015, 132, 1538-1548.	1.6	98
313	Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. Journal of the American Medical Directors Association, 2015, 16, 933-939.	2.5	102
314	Adherence to antihypertensive medications: is prescribing the right pill enough?. Nephrology Dialysis Transplantation, 2015, 30, 1649-1656.	0.7	27
315	Blood Pressure in Chronic Kidney Disease. Hypertension, 2015, 65, 27-28.	2.7	0
316	Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients. Nephrology Dialysis Transplantation, 2015, 30, 724-737.	0.7	80
317	The relationship between thyroid function and estimated glomerular filtration rate in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 282-287.	0.7	84
318	Association of Medical Treatment Nonadherence With All-Cause Mortality in Newly Treated Hypertensive US Veterans. Hypertension, 2014, 64, 951-957.	2.7	45
319	Risk of chronic kidney disease after cancer nephrectomy. Nature Reviews Nephrology, 2014, 10, 135-145.	9.6	56
320	The Relationship Between Ultraviolet Light Exposure and Mortality in Dialysis Patients. American Journal of Nephrology, 2014, 40, 224-232.	3.1	8
321	Comparative Mortality–Predictability Using Alkaline Phosphatase and Parathyroid Hormone in Patients on Peritoneal Dialysis and Hemodialysis. Peritoneal Dialysis International, 2014, 34, 732-748.	2.3	45
322	Observational Modeling of Strict vs Conventional Blood Pressure Control in Patients With Chronic Kidney Disease. JAMA Internal Medicine, 2014, 174, 1442.	5.1	83
323	Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality. JAMA - Journal of the American Medical Association, 2014, 311, 2518.	7.4	760
324	Association of Body Mass Index with Outcomes in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 2088-2096.	6.1	196

#	Article	IF	CITATIONS
325	Obesity Paradox in End-Stage Kidney Disease Patients. Progress in Cardiovascular Diseases, 2014, 56, 415-425.	3.1	281
326	Updates on the Management of Diabetes in Dialysis Patients. Seminars in Dialysis, 2014, 27, 135-145.	1.3	116
327	Effect of Age and Dialysis Vintage on Obesity Paradox in Long-term Hemodialysis Patients. American Journal of Kidney Diseases, 2014, 63, 612-622.	1.9	81
328	Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2014, 63, 650-658.	2.8	127
329	Alkaline phosphatase: Better than <scp>PTH</scp> as a marker of cardiovascular and bone disease?. Hemodialysis International, 2014, 18, 720-724.	0.9	10
330	What is the Role of Lipid Measurements in Endâ€Stage Renal Disease?. Seminars in Dialysis, 2014, 27, 549-552.	1.3	0
331	Restricting Kidney Transplant Waitâ€Listing for Obese Patients: Let's Stop Defending the Indefensible. Seminars in Dialysis, 2014, 27, 1-3.	1.3	7
332	Do FGF23 levels change over time and if yes, what do such changes mean?. Nephrology Dialysis Transplantation, 2014, 29, 12-14.	0.7	2
333	Circulating Angiopoietin-2 levels predict mortality in kidney transplant recipients: a 4-year prospective case-cohort study. Transplant International, 2014, 27, 541-552.	1.6	11
334	Management of hyperkalaemia in chronic kidney disease. Nature Reviews Nephrology, 2014, 10, 653-662.	9.6	148
335	Impact of Achieved Blood Pressures onÂMortality Risk and End-Stage RenalÂDisease Among a Large, DiverseÂHypertension Population. Journal of the American College of Cardiology, 2014, 64, 588-597.	2.8	138
336	Metabolic Acidosis as a Possible Cause of CKD: What Should Clinicians Do?. American Journal of Kidney Diseases, 2014, 64, 481-483.	1.9	9
337	Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. Bone, 2014, 61, 201-207.	2.9	31
338	Why cachexia kills: examining the causality of poor outcomes in wasting conditions. Journal of Cachexia, Sarcopenia and Muscle, 2013, 4, 89-94.	7.3	117
339	Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease. Annals of Internal Medicine, 2013, 159, 233.	3.9	182
340	Comparison of serum cystatin C and creatinine changes after cardiopulmonary bypass in patients with normal preoperative kidney function. International Urology and Nephrology, 2013, 45, 1597-1603.	1.4	9
341	Correlates of low hemoglobin A1c in maintenance hemodialysis patients. International Urology and Nephrology, 2013, 45, 1079-1090.	1.4	8
342	Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrology Dialysis Transplantation, 2013, 28, 2228-2236.	0.7	92

#	Article	IF	Citations
343	Traditional and Novel Dietary Interventions for Preventing Progression of Chronic Kidney Disease., 2013, 23, 241-245.		6
344	Antiâ€Inflammatory and Antiâ€Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AlONID) study: results of the pilotâ€feasibility, doubleâ€blind, randomized, placeboâ€controlled trial. Journal of Cachexia, Sarcopenia and Muscle, 2013, 4, 247-257.	7.3	38
345	Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy. American Journal of Clinical Nutrition, 2013, 97, 1163-1177.	4.7	213
346	Relative contributions of inflammation and inadequate protein intake to hypoalbuminemia in patients on maintenance hemodialysis. International Urology and Nephrology, 2013, 45, 215-227.	1.4	39
347	Racial Differences in Estimated GFR Decline, ESRD, and Mortality in an Integrated Health System. American Journal of Kidney Diseases, 2013, 62, 236-244.	1.9	87
348	Survival Advantage in Black Versus White Men With CKD: Effect of Estimated GFR and Case Mix. American Journal of Kidney Diseases, 2013, 62, 228-235.	1.9	33
349	Outcomes Associated With Microalbuminuria. Journal of the American College of Cardiology, 2013, 61, 1626-1633.	2.8	44
350	Nutritional and Inflammatory Axis of Racial Survival Disparities. Seminars in Dialysis, 2013, 26, 36-39.	1.3	5
351	Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nature Reviews Nephrology, 2013, 9, 99-111.	9.6	145
352	Protein-Energy Wasting as a Risk Factor of Morbidity and Mortality in Chronic Kidney Disease. , $2013$ , , $171-195$ .		0
353	Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2535-2545.	0.7	37
354	Using Hemoglobin A1c to Derive Mean Blood Glucose in Peritoneal Dialysis Patients. American Journal of Nephrology, 2013, 37, 413-420.	3.1	20
355	Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2146-2155.	0.7	75
356	Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrology Dialysis Transplantation, 2013, 28, 2889-2898.	0.7	11
357	A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival. Kidney International, 2013, 84, 795-802.	5.2	118
358	Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 1516-1525.	0.7	30
359	Changes in Body Weight and Subsequent Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1640-1642.	4.5	2
360	Nephrologist Caseload and Hemodialysis Patient Survival in an Urban Cohort. Journal of the American Society of Nephrology: JASN, 2013, 24, 1678-1687.	6.1	22

#	Article	IF	Citations
361	Developing an HbA1c-Based Equation to Estimate Blood Glucose in Maintenance Hemodialysis Patients. Diabetes Care, 2013, 36, 922-927.	8.6	23
362	The Role of Fibroblast Growth Factor-23 in Cardiorenal Syndrome. Nephron Clinical Practice, 2013, 123, 194-201.	2.3	35
363	How Can Erythropoeitinâ€Stimulating Agent Use be Reduced in Chronic Dialysis Patients?. Seminars in Dialysis, 2013, 26, 540-542.	1.3	11
364	Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney International Supplements, 2013, 3, 462-468.	14.2	34
365	Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy. CKJ: Clinical Kidney Journal, 2013, 6, 395-401.	2.9	18
366	Management of mineral and bone disorder after kidney transplantation. Current Opinion in Nephrology and Hypertension, 2012, 21, 389-403.	2.0	49
367	Association of Pre–Kidney Transplant Markers of Mineral and Bone Disorder with Post-Transplant Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1859-1871.	4.5	35
368	Significance of hypo- and hypernatremia in chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 891-898.	0.7	65
369	Glycemic Control and Cardiovascular Mortality in Hemodialysis Patients With Diabetes. Diabetes, 2012, 61, 708-715.	0.6	163
370	Association of Hypo- and Hyperkalemia with Disease Progression and Mortality in Males with Chronic Kidney Disease: The Role of Race. Nephron Clinical Practice, 2012, 120, c8-c16.	2.3	119
371	Mortality Prediction by Surrogates of Body Composition: An Examination of the Obesity Paradox in Hemodialysis Patients Using Composite Ranking Score Analysis. American Journal of Epidemiology, 2012, 175, 793-803.	3.4	133
372	Association of Depression and Antidepressant Use with Mortality in a Large Cohort of Patients with Nondialysis-Dependent CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1793-1800.	4.5	34
373	Association of echocardiographic abnormalities with mortality in men with non-dialysis-dependent chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 694-700.	0.7	22
374	Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 2899-2907.	0.7	17
375	Enter the dragon: a Chinese epidemic of chronic kidney disease?. Lancet, The, 2012, 379, 783-785.	13.7	31
376	Hyponatremia, Hypernatremia, and Mortality in Patients With Chronic Kidney Disease With and Without Congestive Heart Failure. Circulation, 2012, 125, 677-684.	1.6	245
377	Clinical Outcomes in Kidney Transplant Recipients Receiving Long-Term Therapy With Inhibitors of the Mammalian Target of Rapamycin. American Journal of Transplantation, 2012, 12, 379-387.	4.7	27
378	Charlson comorbidity score is a strong predictor of mortality in hemodialysis patients. International Urology and Nephrology, 2012, 44, 1813-1823.	1.4	83

#	Article	IF	CITATIONS
379	Observational Studies Versus Randomized Controlled Trials: Avenues to Causal Inference in Nephrology. Advances in Chronic Kidney Disease, 2012, 19, 11-18.	1.4	74
380	Examining Associations of Circulating Endotoxin With Nutritional Status, Inflammation, and Mortality in Hemodialysis Patients. , 2012, 22, 317-326.		80
381	Accuracy and Limitations of the Diagnosis of Malnutrition in Dialysis Patients. Seminars in Dialysis, 2012, 25, 423-427.	1.3	36
382	Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD?. Nephrology Dialysis Transplantation, 2012, 27, 3056-3062.	0.7	82
383	Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis. Pharmacoepidemiology and Drug Safety, 2012, 21, 1232-1239.	1.9	22
384	Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease. Kidney Research and Clinical Practice, 2012, 31, 12-25.	2.2	7
385	Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia. Experimental & Translational Stroke Medicine, 2012, 4, 24.	3.2	11
386	Roma ethnicity and clinical outcomes in kidney transplant recipients. International Urology and Nephrology, 2012, 44, 945-954.	1.4	9
387	Glycemic Control in Diabetic Dialysis Patients and the Burnt-Out Diabetes Phenomenon. Current Diabetes Reports, 2012, 12, 432-439.	4.2	57
388	Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2012, 59, 58-66.	1.9	68
389	In Reply to â€~Oral Vitamin D Effects on PTH Levels'. American Journal of Kidney Diseases, 2012, 59, 738-739.	1.9	2
390	Diets and enteral supplements for improving outcomes in chronic kidney disease. Nature Reviews Nephrology, 2011, 7, 369-384.	9.6	147
391	Insights Into Nutritional and Inflammatory Aspects of Low Parathyroid Hormone inÂDialysis Patients. , 2011, 21, 100-104.		31
392	Design and Development of a Dialysis Food Frequency Questionnaire., 2011, 21, 257-262.		41
393	DIETARY EGG WHITES FOR PHOSPHORUS CONTROL IN MAINTENANCE HAEMODIALYSIS PATIENTS: A PILOT STUDY. Journal of Renal Care, 2011, 37, 16-24.	1.2	32
394	Association of Serum Phosphorus Level With Anemia in Kidney Transplant Recipients. Transplantation, 2011, 91, 875-882.	1.0	29
395	How KDIGO Will (or Will Not) Influence the Management of Hyperphosphatemia. Seminars in Dialysis, 2011, 24, 35-36.	1.3	1
396	Associations of Body Mass Index and Weight Loss with Mortality in Transplant-Waitlisted Maintenance Hemodialysis Patients. American Journal of Transplantation, 2011, 11, 725-736.	4.7	137

#	Article	IF	Citations
397	Associations of Pretransplant Serum Albumin with Post-Transplant Outcomes in Kidney Transplant Recipients. American Journal of Transplantation, 2011, 11, 1006-1015.	4.7	75
398	Novel Equations to Estimate Lean Body Mass in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 57, 130-139.	1.9	67
399	Role of Nutritional Status and Inflammation in Higher Survival of African American and Hispanic Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 57, 883-93.	1.9	72
400	Association of the Malnutrition-Inflammation Score With Clinical Outcomes in Kidney Transplant Recipients. American Journal of Kidney Diseases, 2011, 58, 101-108.	1.9	70
401	Serum Albumin as a Predictor of Mortality in Peritoneal Dialysis: Comparisons With Hemodialysis. American Journal of Kidney Diseases, 2011, 58, 418-428.	1.9	199
402	Racial and Ethnic Differences in the Association of Body Mass Index and Survival in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 58, 574-582.	1.9	72
403	Wasting in chronic kidney disease. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 9-25.	7.3	218
404	ASTâ€120 for preventing progression of chronic kidney disease: What can we conclude from the available evidence?. Dialysis and Transplantation, 2011, 40, 194-195.	0.2	1
405	Association between the malnutrition-inflammation score and post-transplant anaemia. Nephrology Dialysis Transplantation, 2011, 26, 2000-2006.	0.7	52
406	Diuretics and secondary hyperparathyroidism in chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 1122-1125.	0.7	5
407	High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. American Journal of Clinical Nutrition, 2011, 94, 945-954.	4.7	39
408	Quality-of-Life and Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1100-1111.	4.5	101
409	Serum Erythropoietin Level and Mortality in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2879-2886.	4.5	21
410	Associations of Pretransplant Weight and Muscle Mass with Mortality in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1463-1473.	4.5	154
411	Diagnostic Accuracy of Serum Parathyroid Hormone Levels in Kidney Transplant Recipients with Moderate-to-Advanced CKD. Nephron Clinical Practice, 2011, 118, c78-c85.	2.3	3
412	Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality. Journal of the American Society of Nephrology: JASN, 2011, 22, 956-966.	6.1	253
413	Association of Pretransplant Serum Phosphorus with Posttransplant Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2712-2721.	4.5	19
414	Racial and Ethnic Differences in Mortality of Hemodialysis Patients: Role of Dietary and Nutritional Status and Inflammation. American Journal of Nephrology, 2011, 33, 157-167.	3.1	62

#	Article	IF	CITATIONS
415	Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney International, 2011, 80, 218-224.	5.2	118
416	Association of Pretransplant Glycemic Control With Posttransplant Outcomes in Diabetic Kidney Transplant Recipients. Diabetes Care, 2011, 34, 2536-2541.	8.6	30
417	Novel Lipoprotein Subfraction and Size Measurements in Prediction of Mortality in Maintenance Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2861-2870.	4.5	21
418	Association of Hemodialysis Treatment Time and Dose With Mortality and the Role of Race and Sex. American Journal of Kidney Diseases, 2010, 55, 100-112.	1.9	106
419	Comparing Body Composition Assessment Tests in Long-term Hemodialysis Patients. American Journal of Kidney Diseases, 2010, 55, 885-896.	1.9	79
420	Evaluation of the Malnutrition-Inflammation Score in Kidney Transplant Recipients. American Journal of Kidney Diseases, 2010, 56, 102-111.	1.9	60
421	Dietary Potassium Intake and Mortality in Long-term Hemodialysis Patients. American Journal of Kidney Diseases, 2010, 56, 338-347.	1.9	163
422	Outcomes Associated With Phosphorus Binders in Men With Non–Dialysis-Dependent CKD. American Journal of Kidney Diseases, 2010, 56, 842-851.	1.9	78
423	Body Mass Index, Waist Circumference and Mortality in Kidney Transplant Recipients. American Journal of Transplantation, 2010, 10, 2644-2651.	4.7	147
424	Glycemic Control and Burntâ€Out Diabetes in ESRD. Seminars in Dialysis, 2010, 23, 148-156.	1.3	90
425	Dietary Assessment of Individuals with Chronic Kidney Disease. Seminars in Dialysis, 2010, 23, 359-364.	1.3	69
426	Epidemiology of Dietary Nutrient Intake in ESRD. Seminars in Dialysis, 2010, 23, 353-358.	1.3	48
427	Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodialysis International, 2010, 14, 182-192.	0.9	54
428	Inflammation in Chronic Kidney Disease. , 2010, , 183-197.		2
429	Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2297-2304.	4.5	28
430	Survival Benefits with Vitamin D Receptor Activation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1704-1709.	4.5	15
431	Mid-Arm Muscle Circumference and Quality of Life and Survival in Maintenance Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2258-2268.	4.5	252
432	Outcomes Associated with Serum Calcium Level in Men with Non-Dialysis-Dependent Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 468-476.	4.5	48

#	Article	IF	Citations
433	Survival predictability of lean and fat mass in men and women undergoing maintenance hemodialysis. American Journal of Clinical Nutrition, 2010, 92, 1060-1070.	4.7	88
434	Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney International, 2010, 78, S10-S21.	5.2	109
435	Rate of Kidney Function Decline Associates with Increased Risk of Death. Journal of the American Society of Nephrology: JASN, 2010, 21, 1814-1816.	6.1	12
436	Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clinical Nephrology, 2010, 73, 268-275.	0.7	51
437	Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrology Dialysis Transplantation, 2010, 25, 3003-3011.	0.7	86
438	Association of Cumulatively Low or High Serum Calcium Levels with Mortality in Long-Term Hemodialysis Patients. American Journal of Nephrology, 2010, 32, 403-413.	3.1	80
439	Oral bicarbonate: renoprotective in CKD?. Nature Reviews Nephrology, 2010, 6, 15-17.	9.6	15
440	The Obesity Paradox and Mortality Associated With Surrogates of Body Size and Muscle Mass in Patients Receiving Hemodialysis. Mayo Clinic Proceedings, 2010, 85, 991-1001.	3.0	268
441	Association of Dietary Phosphorus Intake and Phosphorus to Protein Ratio with Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 683-692.	4.5	191
442	Understanding Sources of Dietary Phosphorus in the Treatment of Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 519-530.	4.5	395
443	Association of Relatively Low Serum Parathyroid Hormone With Malnutrition-Inflammation Complex and Survival in Maintenance Hemodialysis Patients. , 2010, 20, 243-254.		56
444	Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. American Journal of Clinical Nutrition, 2009, 90, 407-414.	4.7	140
445	Clinical Outcomes with Active versus Nutritional Vitamin D Compounds in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1529-1539.	4.5	85
446	Association of Serum Total Iron-Binding Capacity and Its Changes Over Time with Nutritional and Clinical Outcomes in Hemodialysis Patients. American Journal of Nephrology, 2009, 29, 571-581.	3.1	67
447	Do Genes Allow Inflammation to Kill or Not to Kill?. Journal of the American Society of Nephrology: JASN, 2009, 20, 1429-1431.	6.1	12
448	Association of Markers of Iron Stores with Outcomes in Patients with Nondialysis-Dependent Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 435-441.	4.5	47
449	Association of Serum Alkaline Phosphatase with Coronary Artery Calcification in Maintenance Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1106-1114.	4.5	126
450	Outcomes Associated with Race in Males with Nondialysis-Dependent Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 973-978.	4.5	38

#	Article	IF	Citations
451	Association of Malnutrition-Inflammation Score With Quality of Life and Mortality in Hemodialysis Patients: A 5-Year Prospective Cohort Study. American Journal of Kidney Diseases, 2009, 53, 298-309.	1.9	302
452	Is It Worth Correcting Hyperparathyroidism if Hyperphosphatemia and Hypocalcemia Worsen? A Cinacalcet Story. American Journal of Kidney Diseases, 2009, 53, 183-188.	1.9	16
453	Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients. American Journal of Kidney Diseases, 2009, 53, 823-834.	1.9	151
454	Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology, 2009, 14, 408-415.	1.6	28
455	Burnt-Out Diabetes: Impact of Chronic Kidney Disease Progression on the Natural Course of Diabetes Mellitus., 2009, 19, 33-37.		72
456	Why Is Protein–Energy Wasting Associated With Mortality in Chronic Kidney Disease?. Seminars in Nephrology, 2009, 29, 3-14.	1.6	175
457	IRON THERAPY IN CHRONIC KIDNEY DISEASE: CURRENT CONTROVERSIES. Journal of Renal Care, 2009, 35, 14-24.	1.2	18
458	Iron and Clinical Outcomes in Dialysis and Non–Dialysis-Dependent Chronic Kidney Disease Patients. Advances in Chronic Kidney Disease, 2009, 16, 109-116.	1.4	15
459	Severity of Hypoalbuminemia Predicts Response to Intradialytic Parenteral Nutrition in Hemodialysis Patients., 2009, 19, 291-297.		18
460	Bone and mineral disorders in pre-dialysis CKD. International Urology and Nephrology, 2008, 40, 427-440.	1.4	66
461	Glycemic Control in Diabetic CKD Patients: Where Do We Stand?. American Journal of Kidney Diseases, 2008, 52, 766-777.	1.9	76
462	Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in Hemodialysis. American Journal of Kidney Diseases, 2008, 52, 727-736.	1.9	133
463	Malnutrition–Inflammation Score for risk stratification of patients with CKD: is it the promised gold standard?. Nature Clinical Practice Nephrology, 2008, 4, 354-355.	2.0	42
464	Battleground. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 168-173.	<b>4.</b> 5	38
465	Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. American Journal of Clinical Nutrition, 2008, 88, 1511-1518.	4.7	291
466	Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2008, 19, 2193-2203.	6.1	217
467	Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney Disease. Archives of Internal Medicine, 2008, 168, 397.	3.8	257
468	Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1691-1701.	<b>4.</b> 5	93

#	Article	IF	CITATIONS
469	Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrology Dialysis Transplantation, 2008, 24, 1232-1237.	0.7	228
470	Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis. American Journal of Clinical Nutrition, 2008, 88, 1485-1494.	4.7	120
471	Ratio of Paricalcitol Dosage to Serum Parathyroid Hormone Level and Survival in Maintenance Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1769-1776.	4.5	57
472	Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opinion on Investigational Drugs, 2008, 17, 451-467.	4.1	31
473	Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney International, 2008, 73, 1296-1302.	5.2	154
474	Vitamin D receptor activation and survival in chronic kidney disease. Kidney International, 2008, 73, 1355-1363.	5.2	79
475	Response to â€Secondary hyperparathyroidism is associated with higher mortality in men with mild to moderate CKD'. Kidney International, 2008, 74, 968.	5.2	0
476	Regional mortality differences in end-stage renal disease: How far can observational studies take us?. Kidney International, 2007, 71, 11-12.	<b>5.2</b>	4
477	Risk factor paradox in wasting diseases. Current Opinion in Clinical Nutrition and Metabolic Care, 2007, 10, 433-442.	2.5	277
478	Inverse Association between Lipid Levels and Mortality in Men with Chronic Kidney Disease Who Are Not Yet on Dialysis. Journal of the American Society of Nephrology: JASN, 2007, 18, 304-311.	6.1	133
479	Association between Serum Lipids and Survival in Hemodialysis Patients and Impact of Race. Journal of the American Society of Nephrology: JASN, 2007, 18, 293-303.	6.1	205
480	Obesity Is Associated with Secondary Hyperparathyroidism in Men with Moderate and Severe Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1024-1029.	4.5	28
481	Serum and Dialysate Potassium Concentrations and Survival in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 999-1007.	4.5	288
482	Racial and survival paradoxes in chronic kidney disease. Nature Clinical Practice Nephrology, 2007, 3, 493-506.	2.0	98
483	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Reverse Epidemiology in Patients with Chronic Kidney Disease Who Are Not Yet on Dialysis. Seminars in Dialysis, 2007, 20, 566-569.	1.3	52
484	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Introduction: The Reverse Epidemiology Controversy. Seminars in Dialysis, 2007, 20, 485-485.	1.3	7
485	Paradoxical Association Between Body Mass Index and Mortality in Men With CKD Not Yet on Dialysis. American Journal of Kidney Diseases, 2007, 49, 581-591.	1.9	199
486	Association of Kidney Function with Mortality in Patients with Chronic Kidney Disease Not Yet on Dialysis: A Historical Prospective Cohort Study. Advances in Chronic Kidney Disease, 2006, 13, 183-188.	1.4	51

#	ARTICLE	IF	CITATIONS
487	Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2006, 17, 1181-1191.	6.1	639
488	Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney International, 2006, 69, 560-564.	5.2	157
489	Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney International, 2006, 70, 771-780.	5.2	804
490	Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrology Dialysis Transplantation, 2006, 21, 1257-1262.	0.7	108
491	Association of Disorders in Mineral Metabolism with Progression of Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 825-831.	4.5	223
492	Association of kidney function with serum lipoprotein(a) level: The Third National Health and Nutrition Examination Survey (1991-1994). American Journal of Kidney Diseases, 2002, 40, 899-908.	1.9	23